NATCO PHARMA Financial Statement Analysis
|
||
|
The Revenues of NATCO PHARMA have decreased by -5.23% YoY .
The Earnings Per Share (EPS) of NATCO PHARMA has increased by 320.49 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NATCO PHARMA Last 5 Annual Financial Results
[BOM: 524816|NSE : NATCOPHARM]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹1,945 Cr | ₹2,052 Cr | ₹1,915 Cr | ₹2,095 Cr | ₹2,185 Cr |
| Expenses | ₹1,681 Cr | ₹1,448 Cr | ₹1,332 Cr | ₹1,300 Cr | ₹1,256 Cr |
| Operating Profit (Excl OI) | ₹264 Cr | ₹604 Cr | ₹583 Cr | ₹795 Cr | ₹928 Cr |
| Other Income | ₹99 Cr | ₹106 Cr | ₹107 Cr | ₹130 Cr | ₹40 Cr |
| Interest | ₹18 Cr | ₹13 Cr | ₹22 Cr | ₹19 Cr | ₹15 Cr |
| Depreciation | ₹143 Cr | ₹117 Cr | ₹100 Cr | ₹81 Cr | ₹66 Cr |
| Profit Before Tax | ₹202 Cr | ₹580 Cr | ₹569 Cr | ₹825 Cr | ₹887 Cr |
| Profit After Tax | ₹170 Cr | ₹442 Cr | ₹458 Cr | ₹642 Cr | ₹695 Cr |
| Consolidated Net Profit | ₹170 Cr | ₹441 Cr | ₹461 Cr | ₹644 Cr | ₹696 Cr |
| Earnings Per Share (Rs) | ₹39.19 | ₹9.32 | ₹24.16 | ₹25.32 | ₹35.31 |
| PAT Margin (%) | 24.83 | 7.67 | 21.23 | 22.26 | 28.12 |
| ROE(%) | 15.66 | 4.06 | 11.27 | 12.71 | 19.75 |
| ROCE(%) | 18.06 | 4.86 | 13.99 | 14.82 | 23.71 |
| Total Debt/Equity(x) | 0.03 | 0.09 | 0.06 | 0.08 | 0.11 |
Key Financials |
||
| Market Cap | : | ₹ 18,469.7 Cr |
| Revenue (TTM) | : | ₹ 3,828.4 Cr |
| Net Profit(TTM) | : | ₹ 1,277.8 Cr |
| EPS (TTM) | : | ₹ 71.3 |
| P/E (TTM) | : | 14.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATCO PHARMA | 2.5% | 8.4% | 79.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
NATCO PHARMA Revenues
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | -5.23 % |
| 5 Yr CAGR | -2.87 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,945 Cr | -5.23 | |
| Mar2022 | ₹2,052 Cr | 7.16 | |
| Mar2021 | ₹1,915 Cr | -8.57 | |
| Mar2020 | ₹2,095 Cr | -4.13 | |
| Mar2019 | ₹2,185 Cr | - | |
NATCO PHARMA Operating Profit
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | -56.36 % |
| 5 Yr CAGR | -27.01 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹264 Cr | -56.36 | |
| Mar2022 | ₹604 Cr | 3.64 | |
| Mar2021 | ₹583 Cr | -26.70 | |
| Mar2020 | ₹795 Cr | -14.39 | |
| Mar2019 | ₹928 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -53.94 % |
| 5 Yr CAGR | -24.85 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 13.55% | -53.94 | |
| Mar2022 | 29.42% | -3.29 | |
| Mar2021 | 30.42% | -19.84 | |
| Mar2020 | 37.95% | -10.68 | |
| Mar2019 | 42.49% | - | |
NATCO PHARMA Profit After Tax
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | -61.44 % |
| 5 Yr CAGR | -29.70 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹170 Cr | -61.44 | |
| Mar2022 | ₹441 Cr | -4.32 | |
| Mar2021 | ₹461 Cr | -28.49 | |
| Mar2020 | ₹644 Cr | -7.44 | |
| Mar2019 | ₹696 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 223.73 % |
| 5 Yr CAGR | -3.06 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 24.83 % | 223.73 | |
| Mar2022 | 7.67 % | -63.87 | |
| Mar2021 | 21.23 % | -4.63 | |
| Mar2020 | 22.26 % | -20.84 | |
| Mar2019 | 28.12 % | - | |
NATCO PHARMA Earnings Per Share (EPS)
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 320.49 % |
| 5 Yr CAGR | 2.64 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹39 | 320.49 | |
| Mar2022 | ₹9.32 | -61.42 | |
| Mar2021 | ₹24 | -4.58 | |
| Mar2020 | ₹25 | -28.29 | |
| Mar2019 | ₹35 | - | |
NATCO PHARMA Return on Capital Employed (ROCE)
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 271.60 % |
| 5 Yr CAGR | -6.58 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 18.06% | 271.60 | |
| Mar2022 | 4.86% | -65.26 | |
| Mar2021 | 13.99% | -5.60 | |
| Mar2020 | 14.82% | -37.49 | |
| Mar2019 | 23.71% | - | |
NATCO PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,031.3 |
| Current MarketCap | : | ₹ 18,469.7 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 2.5% |
8.4% |
79.8% |
| SENSEX | 0.9% |
1.5% |
23.6% |
NATCO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE 250 SMALLCAP | 4.1% | 11.8% | 66.8% |
| S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
| S&P BSE SMALL CAP | 4% | 11.6% | 67.3% |
| S&P BSE 400 MIDSMALLCAP | 3.8% | 9.1% | 62% |
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY FREE SMALL 100 | 4.4% | 13.5% | 81.2% |
| NIFTY SMALLCAP250 | 4.3% | 12.6% | 73.2% |
| NIFTY MID SMALL400 | 3.9% | 9.6% | 64.8% |
| NIFTY SMALLCAP 50 | 3.4% | 13.4% | 83.7% |
| NIFTY PHARMA | 3.2% | 2.2% | 51.4% |
You may also like the below Video Courses
FAQ about NATCO PHARMA Financials
How the annual revenues of NATCO PHARMA have changed ?
The Revenues of NATCO PHARMA have decreased by -5.23% YoY .
How the Earnings per Share (EPS) of NATCO PHARMA have changed?
The Earnings Per Share (EPS) of NATCO PHARMA has increased by 320.49 % YoY .
Check out Intrinsic Value of Peers of NATCO PHARMA
Compare Stock Analytics of Peers of NATCO PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
